Early trial tests common arthritis Drug's potential to hold off blood cancer
NCT ID NCT04370483
Summary
This small, early-stage study is testing whether leflunomide, an anti-inflammatory drug used for rheumatoid arthritis, can delay the progression of high-risk smoldering multiple myeloma to active, symptomatic cancer. Researchers are giving the drug daily to a small group of eligible patients to see if it can control the disease and improve quality of life. The main goal is to see if patients remain progression-free after six months of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.